BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12759532)

  • 1. Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.
    Rossi A; Rosati G; Colarusso D; Manzione L
    Oncology; 2003; 64(4):353-60. PubMed ID: 12759532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
    Chi KH; Chen CH; Chan WK; Chow KC; Chen SY; Yen SH; Chao JY; Chang CY; Chen KY
    J Clin Oncol; 1995 Oct; 13(10):2620-8. PubMed ID: 7595716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
    Meropol NJ; Rustum YM; Creaven PJ; Blumenson LE; Frank C
    Cancer Invest; 1999; 17(1):1-9. PubMed ID: 10999043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A
    J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
    Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL
    Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
    O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
    Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
    Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
    J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
    Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
    Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
    Bin Q; Li J; Liao C; Cao Y; Gao F
    Colorectal Dis; 2011 Aug; 13(8):837-45. PubMed ID: 20050863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF: results of a prospective randomised trial.
    Hejna M; Köstler WJ; Raderer M; Steger GG; Brodowicz T; Scheithauer W; Wiltschke C; Zielinski CC
    Eur J Cancer; 2001 Nov; 37(16):1994-2002. PubMed ID: 11597376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy.
    Rosso M; Blasi G; Gherlone E; Rosso R
    J Chemother; 1997 Oct; 9(5):382-5. PubMed ID: 9373795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor.
    Moore DF; Pazdur R
    Am J Clin Oncol; 1992 Dec; 15(6):464-6. PubMed ID: 1449107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
    J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of granulocyte-macrophage colony-stimulating factor on chemotherapy-induced oral mucositis in non-neutropenic cancer patients.
    Ibrahim EM; al-Mulhim FA
    Med Oncol; 1997 Mar; 14(1):47-51. PubMed ID: 9232612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
    Venturini M; Del Mastro L; Testore F; Danova M; Garrone O; Lanfranco C; Latini F; Sertoli MR; Lionetto R; Queirolo P; Ardizzoni A; Rosso R
    Cancer Chemother Pharmacol; 1996; 38(6):487-94. PubMed ID: 8823488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.
    Müller H; Nakchbandi W; Chatzissavvidis I; Valek V
    Eur J Surg Oncol; 2001 Nov; 27(7):652-61. PubMed ID: 11669594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of high dose 24 hour 5-fluorouracil infusion plus L-leucovorin in advanced colorectal cancer.
    Nobile MT; Barzacch MC; Sanguineti O; Chiara S; Gozza A; Vincenti M; Lavarello A; Cognein P; Lionetto R; Percivale PL; Bertoglio S; Murolo C; Esposito M; Vannozzi MO; Rosso R
    Anticancer Res; 1998; 18(1B):517-21. PubMed ID: 9568171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test.
    Choi K; Lee SS; Oh SJ; Lim SY; Lim SY; Jeon WK; Oh TY; Kim JW
    Clin Nutr; 2007 Feb; 26(1):57-62. PubMed ID: 16949180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
    Soveri LM; Hermunen K; de Gramont A; Poussa T; Quinaux E; Bono P; André T; Österlund P
    Eur J Cancer; 2014 Nov; 50(17):2966-74. PubMed ID: 25266443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intestinal permeability in patients with chemotherapy-induced stomatitis.
    Melichar B; Kohout P; Brátová M; Solichová D; Králícková P; Zadák Z
    J Cancer Res Clin Oncol; 2001 May; 127(5):314-8. PubMed ID: 11355146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.